Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07163624Phase 2Completed

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

Role: lead

NCT07177469Phase 2Completed

UBT251 Injection Phase II Study (Overweight or Obesity)

Role: lead

NCT07134335Phase 2Recruiting

UBT251 Injection Phase II Clinical Study (CKD)

Role: lead

NCT07145151Phase 2Recruiting

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Role: lead

All 4 trials loaded